Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 281 publications
Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026
Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer.
Journal: JAMA network open
Published: July 16, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 20, 2026
Clinical determinants of survival outcomes and acute toxicity after adoptive cellular therapy for solid tumors.
Journal: Frontiers in immunology
Published: April 06, 2026
Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 20, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study.
Journal: NPJ precision oncology
Published: December 10, 2025
Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
Journal: JCO precision oncology
Published: December 05, 2025
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
Journal: ESMO open
Published: October 03, 2025
Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.
Journal: The oncologist
Published: September 30, 2025
Biomarker study of pembrolizumab in patients with advanced rare cancers.
Journal: Cell reports. Medicine
Published: September 24, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.
Journal: Cancer research communications
Published: September 12, 2025
Last Updated: 09/26/2026